You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
Help Center
uSMARTPORT
Download
About
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsInformation about Individual Stocks

Qyuns Therapeutics Co., Ltd. (02509)

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People's Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which is in Phase III

Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
uSMART-Facebook-Page
Headquarters
Sheung Wan
Address: Room 2405-06, 24/F, 308 Central Des Voeux, Sheung Wan, Hong Kong
North DistrictComing Soon
Address: 1718-1721, Level 17 Landmark North, 39 Lung Sum Avenue, Sheung Shui, New Territories, Hong Kong
Email: cs@usmarthk.com
WhatsApp: +852 5989 2641
uSMART Branches(Tsim Sha Tsui, Causeway Bay, Tsuen Wan coming soon)
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907) holding Type 1 Licence for Dealing in Securities, Type 4 Licence for Advising on Securities, Type 6 Licence for Advising on Corporate Finance, and Type 9 Licence for Asset Management.

Copyright © 2022 uSMART . All Rights Reserved.